- 1 Pan-cancer proteogenomic landscape of whole-genome doubling reveals putative
- 2 therapeutic targets in various cancer types
- 3

4 Author names and affiliations

- Eunhyong Chang^{1,2}, Hee Sang Hwang³, Kyu Jin Song^{4,5}, Kwoneel Kim^{6,7}, Min-Sik Kim^{8,9,10}, Se
 Jin Jang^{3,11}, Kwang Pyo Kim^{4,5}, Sungyong You^{12,13}, Joon-Yong An^{1,2,14,*}
- 7
- ⁸ ¹ Department of Integrated Biomedical and Life Science, Korea University, Seoul 02841,
- 9 Republic of Korea
- ² L-HOPE Program for Community-Based Total Learning Health Systems, Korea University,
- 11 Seoul 02841, Republic of Korea
- ³ Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center,
- 13 Seoul 05505, Republic of Korea
- ⁴ Department of Applied Chemistry, Institute of Natural Science, Kyung Hee University,
- 15 Yongin 17104, Republic of Korea
- ⁵ Department of Biomedical Science and Technology, Kyung Hee Medical Science Research
- 17 Institute, Kyung Hee University, Seoul 02453, Republic of Korea
- ⁶ Department of Biology, Kyung Hee University, Seoul 02447, Republic of Korea
- ⁷ Department of Biomedical and Pharmaceutical Sciences, Kyung Hee University, Seoul
- 20 02447, Republic of Korea
- ⁸ Department of New Biology, DGIST, Daegu,42988, Republic of Korea
- ⁹ New Biology Research Center, DGIST, Daegu 42988, Republic of Korea
- ¹⁰ Center for Cell Fate Reprogramming and Control, DGIST, Daegu 42988, Republic of Korea
- ¹¹ Oncoclew Co., Ltd., 31, Ttukseom-ro 1-gil, Seongdong-gu, Seoul 04778, Republic of Korea
- ¹² Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
- ¹³ Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA
- 27 90048, USA
- ¹⁴ School of Biosystem and Biomedical Science, College of Health Science, Korea University,
- 29 Seoul 02841, Republic of Korea
- 30
- 31 ***Correspondence:** joonan30@korea.ac.kr (Joon-Yong An)
- 32

33 Abstract

Background: Whole-genome doubling (WGD) is prevalent in cancer and drives tumor development and chromosomal instability. Driver mutations in mitotic cell cycle genes and cell cycle upregulation have been reported as the major molecular underpinnings of WGD tumors. However, the underlying genomic signatures and regulatory networks involved in gene transcription and kinase phosphorylation remain unclear. Here, we aimed to comprehensively decipher the molecular landscape underlying WGD tumors.

40 *Methods*: We performed a pan-cancer proteogenomic analysis and compared 10 cancer 41 types by integrating genomic, transcriptomic, proteomic, and phosphoproteomic datasets 42 from the Clinical Proteomic Tumor Analysis Consortium (CPTAC). We also integrated the 43 cancer dependency data of each cancer cell line and the survival properties of each cancer 44 patient to propose promising therapeutic targets for patients with WGD.

45 **Results**: Our study delineated distinct copy number signatures characterizing WGD-positive 46 tumors into three major groups: highly unstable genome, focal instability, and tetraploidy. 47 Furthermore, the analysis revealed the heterogeneous mechanisms underlying WGD across 48 cancer types with specific structural variation patterns. Upregulation of the cell cycle and 49 downregulation of the immune response were found to be specific to certain WGD tumor 50 types. Transcription factors (TFs) and kinases exhibit cancer-specific activities, emphasizing 51 the need for tailored therapeutic approaches.

52 **Conclusion**: This study introduces an integrative approach to identify potential TF targets for 53 drug development, highlighting BPTF as a promising candidate for the treatment of head and 54 neck squamous cell carcinoma. Additionally, drug repurposing strategies have been 55 proposed, suggesting potential drugs for the treatment of WGD-associated cancers. Our 56 findings offer insights into the heterogeneity of WGD and have implications for precision 57 medicine approaches for cancer treatment.

58

59 Keywords: Whole-genome doubling, Pan-cancer, Multi-omics, Cancer genomics,
60 Personalized medicine, Genome instability, BPTF, Head and neck squamous cell carcinoma

61 Background

62 Whole-genome doubling (WGD) is prevalent across cancer subtypes, promoting tumor 63 development and generating chromosomal instability (CIN). WGD plays an important role in 64 tumorigenesis by cushioning the deleterious mutations and rapidly accumulating genetic 65 abnormalities. However, WGD is also associated with tolerance to genomic instability, which leads to cell death ¹⁻³. Previous studies have investigated the genomic alterations associated 66 67 with WGD, revealing that TP53 mutations and defects in the E2F-mediated G1 arrest are common in WGD-positive tumors¹. Moreover, gene expression studies have highlighted the 68 69 enrichment of genes involved in cellular proliferation, mitotic spindle formation, and DNA repair, whereas inflammatory pathways are downregulated in WGD-positive tumors². These 70 71 findings depict the overall pan-cancer characteristics of WGD; however, the role of WGD can be highly heterogeneous ^{2,4-7}. 72

73 Recent proteomic studies have delineated novel mechanisms underlying diverse cancer subtypes⁸. These investigations have revealed associations between certain 74 75 multiomic subtypes that are indicative of WGD. For example, in head and neck squamous 76 cell carcinoma (HNSCC), a distinct molecular subtype has been characterized by high CIN and upregulated cell cycle pathways at both the proteome and phosphoproteome levels⁹. 77 78 Similar WGD-associated subtypes have been detected in non-small cell lung cancer (NSCLC), 79 endometrial cancer, breast cancer (BRCA), colon cancer, and glioblastoma (GBM) ¹⁰⁻¹⁴. 80 Despite mounting evidence implicating WGD-related subtypes across multiple cancers, a 81 pan-cancer multiomics investigation focusing on WGD remains elusive. In addition, the 82 proteomic features and kinase activities governing WGD in cancer are yet to be elucidated. 83 Furthermore, the development of therapeutic strategies that specifically target WGD-84 positive tumors remains an unmet need.

In this study, we aimed to conduct a pan-cancer proteogenomic analysis to delineate the genomic and proteomic landscapes of WGD across ten types of cancer by integrating genomic, transcriptomic, proteomic, and phosphoproteomic data sets. Our objective was to characterize the molecular pathways, transcription factor (TF) regulation, and kinase phosphorylation networks enriched in association with the WGD. Finally, we explored the potential drug targets and repositioning strategies for patients with WGDs.

91

92

93 Results

94 Pan-cancer analysis to identify CN signatures underlying WGD

95 We sought to explore the proteogenomic features associated with WGD by analyzing 96 comprehensive genomic, transcriptomic, proteomic, and phosphoproteomic datasets 97 obtained from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) (Figure 1A). The dataset comprised 1,060 patients representing 10 types of cancer: breast cancer (BRCA)¹². 98 clear cell renal cell carcinoma (CCRCC)¹⁵, colon adenocarcinoma (COAD)¹³, glioblastoma 99 (GBM)¹⁴, high-grade serous carcinoma (HGSC)^{16,17}, head and neck squamous cell carcinoma 100 (HNSCC)⁹, lung adenocarcinoma (LUAD)¹¹, lung squamous cell carcinoma (LSCC)¹⁰, 101 pancreatic ductal adenocarcinoma (PDAC)¹⁸, and uterine corpus endometrial carcinoma 102 (UCEC) ¹². By determining the WGD status of each sample, we observed a bimodal 103 104 distribution of patients, indicating the existence of two distinct groups of cancers 105 irrespective of the cancer type (Figure 1B). Consistent with previous estimates, 106 approximately 42% of the tumors (440 of 1,060 samples) exhibited at least 1 occurrence of WGD during their evolutionary process^{1,2}. We also identified substantial variability in the 107 108 occurrence of WGD across different tumor types, with HGSC showing the highest prevalence 109 (83%, 65/78 samples) and PDAC showing the lowest (9.4%, 13/139 samples) (Figure 1C).

110 Mutation signature analyses demonstrated that WGD was associated with specific 111 copy number signatures (Table S1B). Based on the 25 CN signature values of the WGD-112 positive samples, different cancer types exhibited varying combinations of CN signatures, 113 suggesting that the underlying mechanisms of WGD might be distinct across cancer types (Figure 1D). In patients with LSCC, those with WGD showed significant enrichment for CN7 114 $(FDR = 3.11 \times 10^{-5})$, indicating chromothripsis amplification, as well as for CN15 (FDR = 115 2.87x10⁻²), signifying chromosomal loss-of-heterozygosity (LOH) with twice-genome-116 doubling (Figure S1A; Table S1B). Similarly, patients with HNSCC showed significant 117 enrichment of CN15 in WGD-positive samples (FDR = 4.63×10^{-6}). Patients with LUAD showed 118 enrichment of the CN7 signature (FDR = 5.39×10^{-4}). WGD in BRCA and HGSC correlated 119 significantly with CN11, a signature of focal LOH, with two WGD events (BRCA, FDR=1.71x10 120 ⁵; HGSC, FDR=2.68x10⁻¹³), suggesting that WGD in these malignancies occurred within a 121 focally unstable genomic context. A majority of WGD samples from CCRCC, COAD, GBM, 122 123 PDAC, and UCEC were found to be significantly enriched for CN2 (FDR < 0.05), indicating 124 tetraploidy. Based on these observations, we defined three distinct WGD status in LSCC,

LUAD, and HNSCC as "WGD type 1," that in BRCA and HGSC as "WGD type 2," and that in CCRCC, COAD, GBM, PDAC, and UCEC as "WGD type 3." The WGD status was present in a coherent grouping of samples, wherein cancer types with similar CN signatures exhibited spatial proximity (**Figure 1E**).

129 We further evaluated the driver mutations associated with WGD in each tumor type. 130 Despite previous reports suggesting an enrichment of TP53 mutations in WGD tumors across diverse cancers ^{1,2}, we identified a significant enrichment of *TP53* mutations exclusively in 131 132 the WGD-positive samples of BRCA, COAD, UCEC, and LUAD (p < 0.05; Fisher's exact test) 133 (Figure 1F; Table S1C). Although no common gene mutations were identified, we observed 134 that over 100 mutations were significantly enriched in association with WGD in LSCC, LUAD, 135 and HNSCC (WGD type 1), whereas other cancer types exhibited fewer than 15 significant 136 gene mutations associated with WGD. As a highly unstable genome has been linked to a higher tumor mutational burden (TMB) ^{19,20}, we speculated that the TMB would be higher in 137 138 WGD type 1. We found significantly higher TMB in WGD-positive samples than in WGDnegative samples across 10 cancer types ($p = 3.12 \times 10^{-4}$; Wilcoxon rank-sum test) (Figure 139 140 **S1A**), and in LSCC, LUAD, HNSCC, and BRCA when compared across individual cancer types (p 141 < 0.05; Wilcoxon rank-sum test) (Figure S1B). WGD-positive samples in COAD exhibited significantly lower TMB than WGD-negative samples ($p = 2.13 \times 10^{-4}$; Wilcoxon rank-sum test). 142 143 Nevertheless, TP53 and APC mutations remained significantly enriched in samples with WGD in COAD (TP53, $p = 1.75 \times 10^{-3}$; APC, $p = 2.31 \times 10^{-2}$; Fisher's exact test) (Figure 1F). This is 144 145 consistent with the findings of prior investigations suggesting an association between APC mutations and aneuploidy in COAD²¹⁻²³. These observations imply that genomic instability is 146 a catalyst for WGD in LSCC, LUAD, and HNSCC, whereas TP53 and APC mutations may serve 147 148 as primary drivers of WGD in COAD. In summary, our findings revealed distinct CN signatures 149 of WGD, allowing us to define three types of WGD.



150

151 Figure 1. Copy number signatures associated with WGD

152 (A) Schematic representation of the multi-omics datasets collected for each cancer type and 153 the subsequent analysis pipeline. BRCA, breast cancer; CCRCC, Clear cell renal cell carcinoma; 154 COAD, colon adenocarcinoma; GBM, Glioblastoma; HGSC, High-grade serous carcinoma; 155 HNSCC, Head and neck squamous cell carcinoma; LSCC, Lung squamous cell carcinoma; 156 LUAD, Lung adenocarcinoma; PDAC, Pancreatic ductal adenocarcinoma; UCEC, Uterine 157 corpus endometrial carcinoma. (B) Distribution of the WGD fraction within the CPTAC cohort, 158 displaying a bimodal pattern. (C) Prevalence of WGD by cancer type. (D) Heatmap based on 159 copy number signature exposure values in samples with WGD. Copy number signatures were

160 derived from the Catalogue Of Somatic Mutations In Cancer (COSMIC). (E) UMAP plot based on signature exposure values of single-base-substitution, double-base-substitution, indel, 161 162 and copy number alteration. Each dot indicates samples and is colored based on WGD 163 fraction (top) and cancer types (bottom). (F) Dot plot depicting differentially mutated genes 164 in WGD in each cancer type. The position of each dot along the x-axis and the color of the 165 dots indicate signed p-values obtained from Fisher's exact test. Only the top three significant 166 genes were labeled in each cancer type, except for COAD and PDAC, for which only two and 167 one significant genes, respectively, were noted. In LUAD, PTPRN, GRIN2B, ANPEP, and 168 ADGRE1 genes exhibited the same p-values, and TP53 was additionally labeled.

169 170

171 Enrichment of distinct pathways in WGD in each cancer type

172 Previous studies have reported activation of the cell cycle pathway and inactivation of the immune response pathway in tumors with WGD ^{1,2,24,25}. Given the various CN signatures 173 174 underlying WGD across cancer types, we conducted a sample-level pathway enrichment test with 1,060 samples and examined the biological pathways enriched in WGD (Figure 2A). 175 176 Overall, WGD-positive tumors were significantly affected by several pathways (Table S2A), 177 which were subsequently categorized into four major pathway groups: cell motility, immune 178 response, cell cycle, and metabolism. WGD type 1 tumors, characterized by a highly unstable 179 genome, showed significant upregulation of the cell cycle and downregulation of immune response pathways (Figure 2B and 2C), which is consistent with previous reports ^{1,2,24,25}. In 180 181 contrast, WGD type 2 tumors showed significant enrichment in the dTTP metabolism pathway, which is responsible for DNA synthesis and maintenance 26,27 (p < 0.01; Wilcoxon 182 rank-sum test), and the DNA endoreduplication pathway, a known mechanism inducing 183 WGD 28,29 (p < 0.05; Wilcoxon rank-sum test) (Figure 2SA and 2SB). Among other cancer 184 types, WGD tumors in COAD showed significant activation of the Wnt signaling pathway, 185 possibly attributed to APC mutation, in line with the findings of previous studies $^{30-32}$ (p = 186 2.09x10⁻³; Wilcoxon rank-sum test) (Figure 2SC). These results emphasize that upregulation 187 188 of the cell cycle and downregulation of the immune response are specific to WGD type 1 tumors, suggesting diverse functional attributes of WGD across distinct cancer types. 189



190

191 Figure 2. Pathway enrichment in WGD-positive tumors

(A) Normalized enrichment scores (NES) of pathways related to cell motility, immune
 response, cell cycle, and metabolism in WGD-positive tumors. Pathways exhibiting
 significance (FDR < 0.05) and a log fold-change greater than 0.25 are shown. (B–C) Boxplot
 comparing NES score of cell cycle pathway (HALLMARK_E2F_TARGETS) and immune
 response pathway (GOBP_IMMUNE_RESPONSE) between WGD-positive and WGD-negative
 tumors in individual cancer types.

- 198
- 199

200 WGD-specific TFs as potential therapeutic targets

201 To identify potential therapeutic targets for treating WGD across various tumor types, we first estimated TF activity using the TF-target gene interaction network database ³³ and the 202 203 gene expression levels of target genes (see Methods). Out of the 1,134 TFs analyzed, the E2F 204 family and MYC TFs showed significant activation (FDR < 0.05) in pan-cancer WGD tumors, indicating the role of cell cycle regulation in WGD pathophysiology ^{34,35} (Figure 3A; Table 205 206 **S3A**). In contrast, the TFs that were significantly downregulated in the WGD-positive tumors 207 were predominantly associated with immune response pathways. While different TFs were 208 activated in WGD-positive tumors across different cancer types (Figure 3B), E2F1, E2F2, E2F3, 209 E2F4, and MYC were common TFs with significant activation in five cancer types (LSCC, LUAD, 210 HNSCC, BRCA, and PDAC) that showed upregulation of the cell cycle pathway (Figure 2B).

211 Since many TFs have been deemed as 'undruggable' due to their structural 212 complexities and a lack of tractable binding sites ^{36,37}, we introduced an integrative

213 framework to prioritize WGD-activated TFs as putative therapeutic targets (Figures 3C and 214 **3SA–I; Table S3C)**. Among the 99 TFs that exhibited significant activation in each tumor type 215 (FDR < 0.1), we first selected TFs that were detected in CPTAC proteomics data with high 216 confidence (FDR < 0.01). We then filtered TFs exhibiting significantly upregulated protein 217 expression in WGD-positive tumors compared to WGD-negative tumors. We found that the 218 protein expression of IRX2, GLI2, E2F4, and TFDP1 in LSCC, E2F3 in LUAD, BPTF, REST, and 219 SFPQ in HNSCC, and SREBF2 (also known as SREBP2) in BRCA was significantly upregulated 220 (FDR < 0.05, integrated hypothesis test) (Figure 3D). The cancer dependencies of these TFs in 221 each cancer cell line were then evaluated by comparing the dependencies between cells 222 with and without WGD. Among the nine TFs that showed significant upregulation at the 223 protein level, four TFs including IRX2 in LSCC and BPTF, REST, and SFPQ in HNSCC exhibited 224 significantly decreased viability in cells with WGD upon CRISPR-mediated depletion (p < 0.1, 225 Wilcoxon rank-sum test) (Figure 3E). Finally, we selected the TFs with high protein 226 expression levels that were associated with poor prognosis. We found a significant 227 association between high BPTF protein expression and unfavorable prognosis in HNSCC (p =228 0.017, log-rank test) (Figure 3F). BPTF is reported as a co-factor of c-MYC leading to c-MYCdriven proliferation and G1 to S progression ³⁸, and we also observed significant activation of 229 MYC in HNSCC (FDR = 5.66×10^{-3}). Our findings suggest that deactivating BPTF in patients with 230 231 WGD-positive HNSCC could slow down cancer cell proliferation, which may ultimately 232 benefit patient survival.

233 Several TFs did not meet the criteria outlined in our integrative framework; however, they remain potential candidates for further consideration as therapeutic targets. In LSCC, 234 GLI2 showed both significant activation (FDR = 9.37×10^{-2}) and upregulation at both mRNA 235 and protein levels (mRNA, FDR = 1.71×10^{-8} , Wald test; protein, FDR = 1.72×10^{-3} , integrated 236 237 hypothesis test) (Figure S3B; Table S3C). As GLI2 is known to promote cell proliferation and cancer cell survival by upregulating the expression of antiapoptotic proteins in LSCC ³⁹, 238 239 degrading GLI2 may be a promising strategy for the treatment of patients with LSCC 240 harboring WGD. Additionally, TFDP1 and TFDP2, which are partner proteins of the E2F family crucial for the G1 to S phase transition ^{40,41}, were identified as potential therapeutic targets 241 for WGD-positive samples in LSCC, HNSCC, PDAC, and HGSC, in which these TFs were 242 243 significantly activated (FDR < 0.1) (Figure S3A, S3B, S3E, and S3I). In LUAD, E2F3 showed significant activation (FDR = 3.60×10^{-4}) and upregulation at both mRNA and protein levels 244

(mRNA, FDR = 3.16×10^{-5} , Wald test; protein, FDR = 1.83×10^{-3} , integrated hypothesis test) 245 246 (Figure S3C). Therefore, E2F3 inhibitors such as Edifoligide could be a potential treatment for 247 LUAD in patients with WGD. Furthermore, in BRCA, SREBF2 showed significant activation (FDR = 8.67×10^{-2}) along with upregulated protein expression (FDR = 2.42×10^{-2} , integrated 248 249 hypothesis test) (Figure S3D). Targeting SREBF2 could be effective for WGD-positive BRCA 250 samples since SREBF2 is known to regulate the synthesis of cholesterol which is crucial for cancer cell viability in breast cancer cells ⁴²⁻⁴⁴. Taken together, our integrative framework 251 252 incorporated protein expression, cancer dependency, and association with patient survival 253 to delineate effective therapeutic targets among significantly activated TFs. Based on our 254 analysis, we propose that BPTF could potentially serve as a therapeutic target for WGD-255 positive samples in HNSCC, thereby improving patient prognosis.



256

257 Figure 3. Deciphering potential therapeutic targets among activated TFs in WGD

258 (A) Dot plot depicting estimated TF scores in WGD-positive versus WGD-negative tumors 259 across pan-cancer analysis. The top and bottom five TFs, ranked by TF score, are labeled. (B)

260 Significantly upregulated TFs in WGD in each tumor type. The tiles are colored based on the 261 TF estimation score, and TFs meeting the criteria of FDR < 0.05 and TF score > 3 are denoted 262 with asterisks. (C) Schematic diagram showing the filtering processes to identify effective 263 therapeutic targets. The number of TFs or the name of TFs remaining after each step is 264 indicated on the right. (D) Volcano plots of differentially expressed proteins among 265 significant TFs in WGD-positive tumors compared to WGD-negative tumors. (E) Boxplots 266 comparing log₂ cell viability between WGD-positive and WGD-negative cells after depleting genes with CRISPR in each cancer cell line. (F) Kaplan-Meier curve of overall survival based 267 268 on protein expression levels of BPTF in HNSCC.

269 270

271 Drug repurposing strategies to target key kinases in WGD

As kinases are one of the well-known druggable proteins ^{37,45}, we next questioned whether 272 273 we can suggest treatment strategies by deciphering kinase activities in WGD and matching 274 appropriate drugs targeting these kinases. To estimate kinase activities in the WGD in each tumor type, we utilized a kinase-substrate interaction database ⁴⁶ and phosphoprotein 275 276 expression data of substrates (see Methods). Consistently, we observed that cancer types 277 with upregulated cell cycle pathways exhibited CDK1 and CDK2 activation (FDR < 0.1) (Figure 278 4A; Table S4A). The protein expression of these cyclin-dependent kinases was also 279 significantly upregulated (FDR < 0.05, integrated hypothesis test) (Figure 4B). Apart from cell 280 cycle regulation, kinases involved in the DNA damage response and hypoxia-induced 281 autophagy were significantly activated in some tumors. CSNK2A1, which phosphorylates key components of DNA damage and repair pathways ⁴⁷, was significantly activated in LSCC and 282 LUAD (LSCC, FDR = 7.62×10^{-5} ; LUAD, FDR = 1.05×10^{-3}) (Figure 4A; Table S4A). Additionally, in 283 LSCC, PAK4 showed significant activation in WGD (FDR = 6.70×10^{-3}). It is known to promote 284 proliferation and suppress apoptosis ^{48,49}, and its overexpression has been linked to poor 285 prognosis in NSCLC ⁵⁰. In BRCA, both PRKAA2 (also known as AMPK2) and ULK1 were 286 significantly activated (PRKAA2, FDR = 8.34×10^{2} ; ULK1, FDR = 3.21×10^{2}). PRKAA2 induces 287 autophagy during glucose starvation by phosphorylating ULK1 ^{51,52}. These results imply that 288 289 although WGD can drive tumorigenesis by accelerating cell proliferation, it can also induce 290 DNA damage and hypoxia, necessitating kinase activation to inhibit apoptosis, as previously noted ¹⁻³. 291

292 Next, we sought to identify putative drug targets for kinases with upregulated 293 expression in WGD using protein-protein and protein-drug interactions ⁵³ (see Methods). 294 Our analysis revealed that nintedanib was the most promising treatment for WGD in LSCC

295 and LUAD, as it interacts with a majority of significantly activated kinases in these cancers 296 (Figure 4C; Table S4B). Nintedanib is a small-molecule tyrosine kinase inhibitor that is used for NSCLC patients along with docetaxel after the first line of chemotherapy ⁵⁴. For WGD in 297 298 COAD, bosutinib and ruxolitinib were suggested to target PLK1 kinase, a pivotal regulator of mitotic events frequently overexpressed in colon cancers ⁵⁵⁻⁵⁸. These drugs have been 299 reported to induce apoptosis in colon cancer cells ^{59,60}. Sunitinib was recommended as the 300 301 most suitable drug for BRCA patients with WGD, supported by its efficacy in BRCA reported in some studies ^{61,62}, although caution is advised when applying it to metastatic breast 302 cancer patients ⁶³. Overall, our findings unraveled cancer-type-specific kinase activations in 303 WGD contributing to cell proliferation, DNA damage response, and hypoxia-driven 304 305 autophagy. Based on these findings, we proposed FDA-approved drugs for treating patients 306 with WGD in each tumor type.



308 Figure 4. Drug repurposing strategies to target key kinases in WGD

307

309 (A) Kinases with significant upregulation of expression in association with WGD in each 310 tumor type. The tiles are colored based on the kinase estimation score, and kinases showing significant upregulation are denoted with asterisks. (B) Dot plot depicting differentially 311 312 expressed proteins among significantly upregulated kinases in WGD-positive tumors 313 compared to WGD-negative tumors. Kinases with significant upregulation of protein 314 expression (FDR < 0.05 and log2-fold-change > 0), as well as activation (FDR < 0.1), have 315 been labeled. (C) Drug repurposing network for key kinases associated with WGD in each 316 tumor type.

- 317
- 318

319 Discussion

320 Our study elucidated the proteogenomic characteristics of WGD in a cancer-type-specific 321 manner. CN signatures were used to characterize WGD tumors into three major groups: 322 WGD type 1, with a highly unstable genome (LSCC, LUAD, and HNSCC); type 2, with focal 323 instability (BRCA and HGSC); and type 3, with tetraploidy (CCRCC, COAD, GBM, PDAC, and UCEC). This classification seems to align with cancer-specific profiles of structural variation ⁶⁴. 324 325 Triple-negative breast cancer and ovarian cancer are enriched in an SV class, characterized 326 by a high burden of deletions, duplications, and templated insertion chains. LSCC and HNSCC 327 are characterized by an enriched breakage fusion bridge cycle, which is a mechanism of chromosomal instability ⁶⁵. The presence of CN7 and CN15 signatures underscores the 328 occurrence of WGD in a genomically unstable environment at the chromosomal level ⁶⁶. 329

330 While the etiology of CN18 remains unknown, we observed its enrichment in WGDpositive BRCA and GBM. CN18 has been linked to TP53 mutation in BRCA ⁶⁶, and our study 331 332 demonstrates a significant enrichment of TP53 mutation in WGD-positive BRCA samples. 333 This implies CN18 in BRCA may be a WGD signature driven by TP53 mutation. Additionally, 334 CN18 has been associated with hypoxia, which is known to induce polyploid giant cancer cells with stem-like phenotypes in GBM ^{67,68}. As a hypoxic condition in GBM has been linked 335 to advanced tumor stage and invasion ⁶⁹, CN18 in GBM may imply hypoxia-driven WGD with 336 337 an invasive cell state.

In recent studies, WGD tumors have been predominantly characterized by an upregulated cell cycle and a downregulated immune response ^{1,2,24,25}. However, our study demonstrated that this pattern is specific to WGD type 1 (LSCC, LUAD, and HNSCC) and does not entirely represent other types of WGD-positive tumors. For these cancer types, significant activation of E2F and MYC seemed to regulate the cell cycle pathway in WGD-

positive tumors. Instead, the activities of TFs and kinases were more cancer-type-specificthan consistent across WGD types.

345 Our study has important therapeutic implications for WGD tumors. Given the challenges of targeting undruggable TFs^{36,37,45}, we introduced an integrative approach to 346 identify putative TF targets for new drug development, requiring high protein expression 347 levels, increased cancer dependency, and poorer prognosis in patients with WGD. Based on 348 349 these criteria, we identified BPTF as a promising target for treating patients with HNSCC 350 harboring WGD. For kinases associated with WGD, we employed a drug repurposing strategy 351 using search algorithms to identify the most suitable drugs targeting these kinases. Drug 352 repositioning is a cost-effective approach for identifying effective treatments without the need for extensive time or resources for new drug development ⁷⁰. We found nintedanib for 353 354 LSCC and LUAD, bosutinib and ruxolitinib for COAD, and sunitinib for BRCA were 355 recommended as potential drugs for treating WGD patients. Further studies are warranted 356 to evaluate the efficacy of drugs targeting WGD-specific TFs and of repurposed drugs in 357 patient cohorts with WGD. This additional investigation is essential for advancing precision 358 medicine approaches tailored to WGD-associated cancers.

359 Despite our comprehensive analysis, there are limitations within our study. For 360 cancer types included in CPTAC phase 2 (BRCA, COAD, and HGSC), whole-exome sequencing 361 data were utilized to infer WGD, a method potentially less precise than whole-genome 362 sequencing. In addition, our research covered only 1,060 samples across 10 tumor types, 363 indicating the necessity for larger-scale proteogenomic investigations to fully understand 364 WGD characteristics in various cancers. Future studies should consider employing single-cell 365 and spatial proteomics to gain insights into the cellular dynamics and properties of WGD 366 tumor cells. Furthermore, the effectiveness of BPTF inhibitors in WGD-positive HNSCC, 367 among other drugs for WGD-positive tumors, requires further validation. Despite these 368 limitations, our study on the proteogenomic landscape of WGD across cancers could provide 369 therapeutic insights for treating WGD-related subtypes in individual tumor types, supporting 370 the groundwork for future research endeavors.

371

372 Acknowledgments

- 373 This study was supported by the National Research Foundation of Korea (NRF) grant funded
- by the Korea government (NRF-2019M3E5D3073568 to Joon-Yong An) and by the Ministry
- of Science and ICT (NRF-2022R1A2C2013377 to Min-Sik Kim), the Korea Health Industry
- 376 Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea
- 377 (RS-2023-00304839 to Kwoneel Kim), and Korea University to Joon-Yong An. Eunhyong
- 378 Chang received a scholarship from the Kwanjeong Educational Foundation and the Brain
- 379 Korea (BK21) FOUR education program.
- 380

381 **Conflict of interest**

- Kwang Pyo Kim is the CEO of NioBiopharmaceuticals, Inc. Se Jin Jang is the chief executive
 officer of Oncoclew, Co., Ltd. All other authors report no conflict of interest.
- 384

385 Data availability statement

- Public CPTAC datasets are available within 11 publications ⁹⁻¹⁸. Genome and transcriptome
- 387 data were downloaded from the GDC data portal (<u>https://portal.gdc.cancer.gov</u>). Global
- 388 proteomic and phosphoproteomic data were downloaded from LinkedOmics
- 389 (https://www.linkedomics.org/). All data generated during this study are included in
- 390 Supporting Information.
- 391

392 Authors' contributions

- 393 Eunhyong Chang and Joon-Yong An designed the study; Eunhyong Chang analyzed the data;
- Eunhyong Chang, Hee Sang Hwang, Kyu Jin Song, Kwoneel Kim, Min-Sik Kim, Se Jin Jang,
- 395 Kwang Pyo Kim, Sungyong You, Joon-Yong An wrote and reviewed the manuscript; all
- 396 authors approved the final version of the manuscript.
- 397
- 398 **List of abbreviations:** Whole-genome doubling (WGD), Chromosomal instability (CIN), Breast
- 399 cancer (BRCA), Clear cell renal cell carcinoma (CCRCC), Colon adenocarcinoma (COAD),
- 400 Glioblastoma (GBM), High-grade serous carcinoma (HGSC), Head and neck squamous cell 401 carcinoma (HNSCC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LSCC),
- 401 carcinoma (HNSCC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LSCC),
 402 Pancreatic ductal adenocarcinoma (PDAC), Uterine corpus endometrial carcinoma (UCEC)
- 403 Loss-of-heterozygosity (LOH), Tumor mutational burden (TMB), Copy number (CN),
- 404 Transcription factor (TF)
- 405

406 Methods

407 Data collection and preprocessing

408 We obtained genomic, transcriptomic, global proteomic, and phosphoproteomic data from 409 the Clinical Proteomic Tumor Analysis Consortium. The mutation annotation format file for 410 each sample and the segment-level copy number variant (CNV) text file for the samples in CPTAC phase-3 (comprising clear cell renal cell carcinoma [CCRCC], GBM, HNSCC, lung 411 412 squamous cell carcinoma [LSCC], lung adenocarcinoma [LUAD], pancreatic ductal 413 adenocarcinoma [PDAC], and uterine corpus endometrial carcinoma [UCEC]) were 414 downloaded from the GDC data portal (https://portal.gdc.cancer.gov). Transcriptomic data 415 were downloaded from the GDC data portal. Global proteomic and phosphoproteomic data 416 were downloaded from LinkedOmics (https://www.linkedomics.org/).

To standardize the global phosphoprotein data across various cancer types, we initially normalized the data using z-scores. Subsequently, global proteins and phosphoproteins with > 30% missing values in each cancer-type sample were excluded, followed by k-nearest neighbor imputation with k=5 to address missing values.

421

422 CNV calling and WGD detection

As segment-level CN data for BRCA, COAD, and HGSC were unavailable, we acquired BAM files from the GDC data portal and performed the CNV calling process. FACETS v0.16.0⁷¹ was employed to discern allele-specific CN information. The input for FACETS consisted of paired tumor-normal BAM files and a VCF file containing common and germline polymorphic sites downloaded from https://www.ncbi.nlm.nih.gov/variation/docs/human_variation_vcf/.

Using major CN and minor CN data derived from segment-level CNV data, we defined samples as "WGD-positive" if over 50% of their autosomal genome exhibited a major CN greater than or equal to two¹.

431

432 Mutational signature analysis

We conducted a mutational signature analysis using the COSMIC signature database v3 ⁷² and R package Sigminer v2.1.5 ⁷³. Non-negative matrix factorization was employed to determine the number of signature groups or factorization ranks. This involved creating a tumor-by-component matrix with 50 runs and checking the ranks ranging from 2 to 12. Each signature was identified using the COSMIC signature with the highest cosine similarity.

438 Subsequently, hierarchical clustering was performed, and the samples were assigned to one

439 of the signatures based on the consensus matrix.

440

441 Analysis of differential expression

To discern the differentially expressed genes between WGD-positive and WGD-negative samples, we employed the "DESeq" function from the DESeq2 R package ⁷⁴. The raw count data were used for the generation of a DESeqDataSet using the "DESeqDataSetFromMatrix" function. Following a variance stabilizing transformation and the exclusion of data points with a mean raw count less than 50, we conducted the differential expression analysis utilizing the "DESeq" function, which is grounded in the negative binomial distribution. The DEG analysis was performed using the following formula:

$design = \sim WGD.status$

To detect the differential expression of global and phospho-proteins in the WGD samples, we employed an integrated hypothesis testing method following the methodology proposed by Hwang et al ⁷⁵. Briefly, we performed t-tests, median difference tests, and Wilcoxon tests and combined the p-values from the statistical tests using Stouffer's method. This approach enhances the accuracy of identifying true-positive data elements compared with traditional methods when applied to biological data.

455

456 **Gene set enrichment analysis**

457 We conducted a gene set enrichment analysis to elucidate the activated biological pathways in each sample. The "zscore" function from the R package GSVA ⁷⁶ was utilized for analyzing 458 459 transcriptome, global proteome, and phospho-proteome data. Pathways from various 460 databases, including hallmark ("h.all.v2023.1.Hs.symbols.gmt.txt"), KEGG 461 ("c2.cp.kegg.v2023.1.Hs.symbols.gmt.txt"), Reactome ("c2.cp.reactome.v2023.1.Hs.symbols.gmt.txt"), GO ("c5.go.v2023.1.Hs.symbols.gmt.txt"), 462 463 and Wikipathway ("c2.cp.wikipathways.v2023.1.Hs.symbols.gmt.txt") sourced from MSigDB 464 were incorporated into the gene set variation analysis. Subsequently, we performed a t-test 465 between WGD-positive tumors and WGD-negative tumors to identify significantly regulated 466 pathways in the context of WGD.

467

468 Estimation of transcription factor and kinase activity

469 We used the data corresponding to transcription factor (TF)-target interactions from CollecTRI ⁷⁷ to estimate TF activity. The log-2-fold change values derived from the analysis of 470 471 differentially expressed genes (DEGs) served as inputs for the identification of TF activity in 472 WGD-positive samples. For estimating kinase activity, we employed kinase-substrate interactions sourced from OmniPathR⁴⁶. The log-2-fold change values obtained from the 473 474 analysis of differentially expressed phosphorylated proteins were used as inputs to identify 475 the kinase activity in WGD-positive samples. Subsequently, we employed the "run mlm" function within the decoupleR R package ³³ to infer both TF and kinase activities, with the 476 477 minimum size of regulons set to 1.

478

479 **Cancer dependency and druggability analysis**

480 For the comparison of cancer dependencies between WGD-positive and WGD-negative cells, 481 downloaded we "CRISPR (DepMap Public 23Q2+Score, Chronos)," "RNAi 482 (Achilles+DRIVE+Marcotte, DEMETER2)," and "Aneuploidy" data for each cancer cell line from DepMap (https://depmap.org/portal/). We subset the cell lines with annotated 483 484 genome doubling statuses. Cell lines with one or more instances of genome doubling were 485 classified as WGD-positive, whereas those without genome doubling were categorized as WGD-negative. We conducted a one-sided Wilcoxon rank-sum test to assess whether the 486 487 WGD-positive cells exhibited lower viability than the WGD-negative cells. To evaluate the druggability of each TF, we used the DGIdb (v5.0.5)⁷⁸. TFs lacking interactions with drugs 488 489 were deemed "undruggable," those with interactions with FDA-approved drugs were designated as "FDA-approved," and those interacting with known drugs but not with FDA-490 491 approved ones were labeled as "druggable."

492

493 Survival analysis

The Kaplan–Meier estimation model was used to perform survival analysis. The survival duration of the patients and death events were used as inputs for the analysis. To identify the TFs associated with poor prognosis, we compared survival curves between samples with the top 50% and bottom 50% protein expression for each significantly activated TF in WGD (false discovery rate [FDR] < 0.1).

499

500 **Drug repurposing network analysis**

DrugSt. One (v1.2.0) ⁵³ was used to build the drug repurposing network. Significantly upregulated kinases (FDR < 0.1) in the WGD for each tumor type were used as inputs for the search algorithms. NeDRex (v2.21.0) was used for protein-protein and protein-drug interaction searches. For the protein-protein interaction network, we used a multi-Steiner algorithm, setting the number of trees to five, tolerance to five, and hub penalty to 0.5. For the protein-drug interaction network, we used a harmonic centrality algorithm, setting the hub penalty to 0.5 and the result size to 50 and excluding indirect and non-approved drugs.

509 Supplemental tables

- 510 Table S1.xlsx: Sample overview and copy number signatures associated with WGD
- 511 Table S2.xlsx: Enriched pathways in WGD
- 512 Table S3.xlsx: Activated transcription factor in WGD and their druggability
- 513 Table S4.xlsx: Activated kinases in WGD and drug repurposing network

514

515 Supplemental figures



516YesNoLsicLuiadHNisc517Figure S1. Tumor mutation burden in WGD

- 518 (A) Violin plot comparing tumor mutation burden between WGD-positive and WGD-negative
- 519 tumors across 10 cancer types. (B) Boxplots comparing tumor mutation burden between
- 520 WGD-positive and WGD-negative tumors within each cancer type.
- 521

522



523

524 **Figure S2. Pathway enrichment in WGD-positive tumors**

525 (A-C) Boxplot comparing Normalized enrichment scores (NES) score of dTTP metabolism 526 (GOBP DTTP METABOLIC PROCESS), endoreduplication pathway DNA pathway 527 (GOBP DNA ENDOREDUPLICATION), and Wnt signaling pathway 528 (HALLMARK WNT BETA CATENIN SIGNALING) between WGD-positive and WGD-negative 529 tumors in individual cancer types. 530



- 531 Trigure S3. Activated TFs in WGD in each cancer type
- 533 (A-I) Significantly upregulated TFs in WGD in each cancer type are shown. Significant
- features are indicated as an asterisk (TF score, FDR < 0.05; DEG, FDR < 0.05; DEP, FDR < 0.05;
- 535 CRISPR, p < 0.1; RNAi, p < 0.1; Prognosis, p < 0.05).
- 536
- 537

538 References

5391.Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and540prognosis of advanced cancers. Nat Genet. Aug 2018;50(8):1189-1195. doi:10.1038/s41588-541018-0165-1

Quinton RJ, DiDomizio A, Vittoria MA, et al. Whole-genome doubling confers unique
genetic vulnerabilities on tumour cells. *Nature*. Feb 2021;590(7846):492-497.
doi:10.1038/s41586-020-03133-3

5453.Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number546alteration. Nat Genet. Oct 2013;45(10):1134-40. doi:10.1038/ng.2760

Lopez S, Lim EL, Horswell S, et al. Interplay between whole-genome doubling and the
 accumulation of deleterious alterations in cancer evolution. *Nat Genet*. Mar 2020;52(3):283 293. doi:10.1038/s41588-020-0584-7

550 5. Ganem NJ, Cornils H, Chiu S-Y, et al. Cytokinesis failure triggers hippo tumor 551 suppressor pathway activation. *Cell*. 2014;158(4):833-848.

552 6. Senovilla L, Vitale I, Martins I, et al. An immunosurveillance mechanism controls 553 cancer cell ploidy. *Science*. 2012;337(6102):1678-1684.

554 7. Chang E, An J-Y. Whole-genome doubling is a double-edged sword: the 555 heterogeneous role of whole-genome doubling in various cancer types. *BMB reports*. 556 2024:6157-6157.

Heo YJ, Hwa C, Lee GH, Park JM, An JY. Integrative Multi-Omics Approaches in Cancer
 Research: From Biological Networks to Clinical Subtypes. *Mol Cells*. Jul 31 2021;44(7):433 443. doi:10.14348/molcells.2021.0042

Huang C, Chen L, Savage SR, et al. Proteogenomic insights into the biology and
treatment of HPV-negative head and neck squamous cell carcinoma. *Cancer Cell*. Mar 8
2021;39(3):361-379 e16. doi:10.1016/j.ccell.2020.12.007

56310.Satpathy S, Krug K, Jean Beltran PM, et al. A proteogenomic portrait of lung564squamous cell carcinoma. Cell. Aug 5 2021;184(16):4348-4371 e40.565doi:10.1016/j.cell.2021.07.016

566 11. Gillette MA, Satpathy S, Cao S, et al. Proteogenomic Characterization Reveals
567 Therapeutic Vulnerabilities in Lung Adenocarcinoma. *Cell*. Jul 9 2020;182(1):200-225 e35.
568 doi:10.1016/j.cell.2020.06.013

569 12. Krug K, Jaehnig EJ, Satpathy S, et al. Proteogenomic Landscape of Breast Cancer
570 Tumorigenesis and Targeted Therapy. *Cell.* Nov 25 2020;183(5):1436-1456 e31.
571 doi:10.1016/j.cell.2020.10.036

572 13. Vasaikar S, Huang C, Wang X, et al. Proteogenomic Analysis of Human Colon Cancer
573 Reveals New Therapeutic Opportunities. *Cell*. May 2 2019;177(4):1035-1049 e19.
574 doi:10.1016/j.cell.2019.03.030

575 14. Wang LB, Karpova A, Gritsenko MA, et al. Proteogenomic and metabolomic
576 characterization of human glioblastoma. *Cancer Cell*. Apr 12 2021;39(4):509-528 e20.
577 doi:10.1016/j.ccell.2021.01.006

578 15. Clark DJ, Dhanasekaran SM, Petralia F, et al. Integrated Proteogenomic
579 Characterization of Clear Cell Renal Cell Carcinoma. *Cell*. Oct 31 2019;179(4):964-983 e31.
580 doi:10.1016/j.cell.2019.10.007

16. McDermott JE, Arshad OA, Petyuk VA, et al. Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability. *Cell Rep Med*. Apr 21 2020;1(1)doi:10.1016/j.xcrm.2020.100004

Hu Y, Pan J, Shah P, et al. Integrated Proteomic and Glycoproteomic Characterization
of Human High-Grade Serous Ovarian Carcinoma. *Cell Rep.* Oct 20 2020;33(3):108276.
doi:10.1016/j.celrep.2020.108276

18. Cao L, Huang C, Cui Zhou D, et al. Proteogenomic characterization of pancreatic
ductal adenocarcinoma. *Cell*. Sep 16 2021;184(19):5031-5052 e26.
doi:10.1016/j.cell.2021.08.023

Second Second

593 20. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer 594 genomes reveals the landscape of tumor mutational burden. *Genome Med.* Apr 19 595 2017;9(1):34. doi:10.1186/s13073-017-0424-2

596 21. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *cell*. 597 1990;61(5):759-767.

598 22. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. *Nature reviews cancer*. 2001;1(1):55-67.

600 23. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal 601 tumorigenesis. *Nature*. 1992;359(6392):235-237.

Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of
immune evasion and with reduced response to immunotherapy. *Science*. Jan 20
2017;355(6322)doi:10.1126/science.aaf8399

Cohen-Sharir Y, McFarland JM, Abdusamad M, et al. Aneuploidy renders cancer cells
vulnerable to mitotic checkpoint inhibition. *Nature*. Feb 2021;590(7846):486-491.
doi:10.1038/s41586-020-03114-6

608 26. Nordlund P, Reichard P. Ribonucleotide reductases. *Annu Rev Biochem*. 2006;75:681609 706. doi:10.1146/annurev.biochem.75.103004.142443

Chabes A, Georgieva B, Domkin V, Zhao X, Rothstein R, Thelander L. Survival of DNA
damage in yeast directly depends on increased dNTP levels allowed by relaxed feedback
inhibition of ribonucleotide reductase. *Cell*. 2003;112(3):391-401.

61328.Davoli T, Denchi EL, de Lange T. Persistent telomere damage induces bypass of614mitosis and tetraploidy. Cell. Apr 2 2010;141(1):81-93. doi:10.1016/j.cell.2010.01.031

29. Zeng J, Hills SA, Ozono E, Diffley JFX. Cyclin E-induced replicative stress drives p53dependent whole-genome duplication. *Cell*. Feb 2 2023;186(3):528-542 e14.
doi:10.1016/j.cell.2022.12.036

618 30. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with β-619 catenin. *Science*. 1993;262(5140):1731-1734.

Su L-K, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein
with catenins. *Science*. 1993;262(5140):1734-1737.

622 32. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-623 catenin-Tcf complex in APC-/- colon carcinoma. *Science*. 1997;275(5307):1784-1787.

33. Badia-i-Mompel P, Vélez Santiago J, Braunger J, et al. decoupleR: ensemble of
computational methods to infer biological activities from omics data. *Bioinformatics Advances*. 2022;2(1):vbac016.

627 34. Dyson N. The regulation of E2F by pRB-family proteins. *Genes & development*. 628 1998;12(15):2245-2262.

Bretones G, Delgado MD, Leon J. Myc and cell cycle control. *Biochim Biophys Acta*.
May 2015;1849(5):506-16. doi:10.1016/j.bbagrm.2014.03.013

36. Henley MJ, Koehler AN. Advances in targeting 'undruggable' transcription factors
with small molecules. *Nat Rev Drug Discov*. Sep 2021;20(9):669-688. doi:10.1038/s41573021-00199-0

37. Xie X, Yu T, Li X, et al. Recent advances in targeting the "undruggable" proteins: from
drug discovery to clinical trials. *Signal Transduct Target Ther*. Sep 6 2023;8(1):335.
doi:10.1038/s41392-023-01589-z

837 38. Richart L, Carrillo-de Santa Pau E, Rio-Machin A, et al. BPTF is required for c-MYC
638 transcriptional activity and in vivo tumorigenesis. *Nat Commun.* Jan 5 2016;7:10153.
639 doi:10.1038/ncomms10153

640 39. Huang L, Walter V, Hayes DN, Onaitis M. Hedgehog-GLI signaling inhibition 641 suppresses tumor growth in squamous lung cancer. *Clin Cancer Res.* Mar 15 642 2014;20(6):1566-75.doi:10.1158/1078-0432.CCR-13-2195

643 40. Girling R, Partridge JF, Bandara LR, et al. A new component of the transcription factor 644 DRTF1/E2F. *Nature*. 1993;362(6415):83-87.

645 41. Lam EW-F, La Thangue NB. DP and E2F proteins: coordinating transcription with cell 646 cycle progression. *Current opinion in cell biology*. 1994;6(6):859-866.

647 42. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. *Cell*.
648 Jan 13 2006;124(1):35-46. doi:10.1016/j.cell.2005.12.022

649 43. Bengoechea-Alonso MT, Ericsson J. SREBP in signal transduction: cholesterol
650 metabolism and beyond. *Curr Opin Cell Biol*. Apr 2007;19(2):215-22.
651 doi:10.1016/j.ceb.2007.02.004

652 44. Griffiths B, Lewis CA, Bensaad K, et al. Sterol regulatory element binding protein653 dependent regulation of lipid synthesis supports cell survival and tumor growth. *Cancer &*654 *metabolism*. 2013;1:1-21.

45. Peng F, Liao M, Qin R, et al. Regulated cell death (RCD) in cancer: key pathways and
targeted therapies. *Signal Transduct Target Ther*. Aug 13 2022;7(1):286. doi:10.1038/s41392022-01110-y

46. Turei D, Korcsmaros T, Saez-Rodriguez J. OmniPath: guidelines and gateway for
literature-curated signaling pathway resources. *Nat Methods*. Nov 29 2016;13(12):966-967.
doi:10.1038/nmeth.4077

47. Rabalski AJ, Gyenis L, Litchfield DW. Molecular Pathways: Emergence of Protein
Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and
Repair Pathways in Cancer Cells. *Clin Cancer Res.* Jun 15 2016;22(12):2840-7.
doi:10.1158/1078-0432.CCR-15-1314

665 48. Callow MG, Clairvoyant F, Zhu S, et al. Requirement for PAK4 in the anchorage666 independent growth of human cancer cell lines. *J Biol Chem*. Jan 4 2002;277(1):550-8.
667 doi:10.1074/jbc.M105732200

Li X, Minden A. PAK4 functions in tumor necrosis factor (TNF) alpha-induced survival
pathways by facilitating TRADD binding to the TNF receptor. J Biol Chem. Dec 16
2005;280(50):41192-200. doi:10.1074/jbc.M506884200

671 50. Cai S, Ye Z, Wang X, et al. Overexpression of P21-activated kinase 4 is associated with
672 poor prognosis in non-small cell lung cancer and promotes migration and invasion. *J Exp Clin*673 *Cancer Res.* May 15 2015;34(1):48. doi:10.1186/s13046-015-0165-2

51. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol*. Feb 2011;13(2):132-41. doi:10.1038/ncb2152

52. Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphorylation of ULK1 (hATG1) by
AMP-activated protein kinase connects energy sensing to mitophagy. *Science*.
2011;331(6016):456-461.

53. Maier A, Hartung M, Abovsky M, et al. Drugst. One-A plug-and-play solution for online systems medicine and network-based drug repurposing. *Arxiv*. 2023;

68154.Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. J Med682Chem. Feb 12 2015;58(3):1053-63. doi:10.1021/jm501562a

683 55. Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G, Marshall LA. The human polo-684 like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the 685 cdc25C phosphatase. *Cellular signalling*. 2000;12(6):405-411.

56. Dai W, Wang Q, Traganos F. Polo-like kinases and centrosome regulation. *Oncogene*.
587 Sep 9 2002;21(40):6195-200. doi:10.1038/sj.onc.1205710

57. Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. *Cancer Sci*. Feb 2003;94(2):148-52. doi:10.1111/j.1349-7006.2003.tb01411.x

58. Han D-p, Zhu Q-l, Cui J-t, et al. Polo-like kinase 1 is overexpressed in colorectal cancer
and participates in the migration and invasion of colorectal cancer cells. *Medical science monitor: international medical journal of experimental and clinical research*.
2012;18(6):BR237.

69559.Mologni L, Cleris L, Magistroni V, et al. Valproic acid enhances bosutinib cytotoxicity696in colon cancer cells. Int J Cancer. Apr 15 2009;124(8):1990-6. doi:10.1002/ijc.24158

697 60. Li X, Wang Z, Zhang S, Yao Q, Chen W, Liu F. Ruxolitinib induces apoptosis of human 698 colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis. *Oncol Lett*. May 699 2021;21(5):352. doi:10.3892/ol.2021.12613

Korashy HM, Maayah ZH, Al Anazi FE, et al. Sunitinib Inhibits Breast Cancer Cell
Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NFkappaB Signaling Pathways. *Anticancer Res.* Sep 2017;37(9):4899-4909.
doi:10.21873/anticanres.11899

Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral
multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously
treated with an anthracycline and a taxane. J Clin Oncol. Apr 10 2008;26(11):1810-6.
doi:10.1200/JCO.2007.14.5375

Wang D, Xiao F, Feng Z, et al. Sunitinib facilitates metastatic breast cancer spreading
by inducing endothelial cell senescence. *Breast Cancer Res.* Sep 29 2020;22(1):103.
doi:10.1186/s13058-020-01346-y

64. Hadi K, Yao X, Behr JM, et al. Distinct Classes of Complex Structural Variation
Uncovered across Thousands of Cancer Genome Graphs. *Cell.* Oct 1 2020;183(1):197-210
e32. doi:10.1016/j.cell.2020.08.006

McClintock B. The behavior in successive nuclear divisions of a chromosome broken
at meiosis. *Proceedings of the National Academy of Sciences*. 1939;25(8):405-416.

56. Steele CD, Abbasi A, Islam SMA, et al. Signatures of copy number alterations in
human cancer. *Nature*. Jun 2022;606(7916):984-991. doi:10.1038/s41586-022-04738-6

718 67. Qu Y, Zhang L, Rong Z, He T, Zhang S. Number of glioma polyploid giant cancer cells
719 (PGCCs) associated with vasculogenic mimicry formation and tumor grade in human glioma.
720 Journal of Experimental & Clinical Cancer Research. 2013;32:1-7.

721 68. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic 722 microenvironment maintains glioblastoma stem cells and promotes reprogramming towards

723 cancer stem cell phenotype. Cell Cycle. Oct 15 2009;8(20):3274-84. а 724 doi:10.4161/cc.8.20.9701 Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of 725 69. 726 proliferation and invasion. Neuro Oncol. Dec 2014;16(12):1575-84. 727 doi:10.1093/neuonc/nou147 728 Pushpakom S, Iorio F, Evers PA, et al. Drug repurposing: progress, challenges and 70. 729 recommendations. Nat Rev Drug Discov. Jan 2019;18(1):41-58. doi:10.1038/nrd.2018.168 730 71. Shen R. Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity 731 analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. Sep 19 732 2016;44(16):e131. doi:10.1093/nar/gkw520 733 72. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In 734 Cancer. Nucleic Acids Res. Jan 8 2019;47(D1):D941-D947. doi:10.1093/nar/gky1015 735 73. Wang S, Li H, Song M, et al. Copy number signature analysis tool and its application in 736 prostate cancer reveals distinct mutational processes and clinical outcomes. PLoS Genet. 737 May 2021;17(5):e1009557. doi:10.1371/journal.pgen.1009557 738 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 74. 739 RNA-seg data with DESeg2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8 740 Hwang D, Rust AG, Ramsey S, et al. A data integration methodology for systems 75. 741 biology. Proceedings of the National Academy of Sciences. 2005;102(48):17296-17301. 742 76. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC bioinformatics. 2013;14:1-15. 743 744 77. Muller-Dott S, Tsirvouli E, Vazquez M, et al. Expanding the coverage of regulons from 745 high-confidence prior knowledge for accurate estimation of transcription factor activities. 746 Nucleic Acids Res. Nov 10 2023;51(20):10934-10949. doi:10.1093/nar/gkad841 747 78. Cannon M, Stevenson J, Stahl K, et al. DGIdb 5.0: rebuilding the drug-gene interaction 748 database for precision medicine and drug discovery platforms. Nucleic Acids Res. Jan 5 749 2024;52(D1):D1227-D1235. doi:10.1093/nar/gkad1040

750